HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Why Did Novartis/1A Pharma Withdraw Its Paracetamol Liquid From The German Market?

Executive Summary

HBW Insight chats with general manager of Novartis' German subsidiary 1A Pharma about the firm's exit from the country's children's fever category. An inflexible price system for reimbursable medicines and inflationary pressures all contributed to the decision, Michael Klein explains, which has left only two manufacturers supplying the OTC liquid paracetamol market.

You may also be interested in...



German Generic Reform To Relax Pediatric Pricing

Germany’s Bundesministerium für Gesundheit is reworking the country’s off-patent drug legislation to allow for more flexible pricing.

PAGB Calls Out ‘Partial And Incomplete’ Reports Of UK OTC Cough & Cold Shortages

There are no OTC analgesic supply issues in UK despite higher than normal demand, says consumer heathcare industry association PAGB in response to what it labels partial and incomplete reporting” in the country's media. HBW Insight looks at NielsenIQ market data for the week ending 7 Janurary to get behind the headlines. 

German OTC Market News: Allergy, Pain And Sleep Launches From Sanofi, Teva And P&G

The latest German consumer healthcare launches: Sanofi adds bilastine antihistamine to Allegra range; Teva's Ratiopharm delivers paracetamol and ibuprofen combo thanks to Rx-to-OTC switch; and P&G livens up WICK ZzzQuil sleep aid gummies with tropical fruit flavour. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel